Figure 3.

4MU prevents vascular remodelling and pulmonary hypertension. IF‐stained lung sections (A) for αSMA (white or red signals) and Has1 (violet/purple signals); Has2 (green signals); or Has3 (green signals) from mice treated with PBS + vehicle, bleomycin (BLM) + vehicle, or BLM + 4MU. Vascular remodelling determined morphometrically (B); RVSP (C); Fulton index determined from measuring dry weights of RV and LV + septum (D); arterial oxygen (SPO₂) determined by pulse oximetry (E) from PBS + vehicle, PBS + 4MU, BLM + vehicle and BLM + 4MU treatment groups. Data are shown as scatter plot showing the mean ± SD. * P ≤ 0.05, significant difference between PBS + vehicle and BLM + vehicle treatment; ANOVA. # P < 0.05, significant difference between BLM + vehicle and BLM + 4MU treatment; ANOVA. The scale bar represents 50 μm. The N used for these studies are 6 (PBS + vehicle); 6 (PBS + 4MU); 7 (BLM + vehicle); 5 (BLM + 4MU) for panel B; and 10 (PBS + vehicle) for panel B and 10 (PBS + 4MU); 10 (BLM + vehicle); and 8 (BLM + 4MU) for panels C, D and E. Variations in the N are due to violation of a predetermined criteria: inadequate inflation of the lung (C) or heart rate below 250 BPM at the time of RVSP or inability to perform pulse oximetry determination (C–E).